Odaily
Oct 22, 2026

MRNA falls 24.6% over 24 hours, trades at 187.71 USDT

MRNA posted sharp losses in the latest market update cited by Odaily. According to data from MSX.COM, the token was down 24.6% over the past 24 hours and had also fallen 16.4% in the last hour. The quoted price at the time of the update was 187.71 USDT. No additional trading context, volume data, or catalyst was provided in the brief. The item was published as a 7x24 market flash and focused only on the latest percentage declines and spot price.

580
MRNA falls 24.6% over 24 hours, trades at 187.71 USDT
Moderna
Oct 21, 2026

Moderna jumps 11% in two sessions as whale short nears liquidation before cancer data release

Moderna shares extended their rebound ahead of a closely watched cancer therapy data presentation, rising 4.07% and 6.69% over the past two U.S. trading sessions for a combined gain of about 11.04%. The stock last closed at $242.08 and touched an intraday high of $243.98, while the corresponding Hyperliquid contract traded at $241.07, up about 5.71% over 24 hours. The move comes before detailed Phase 3 results for intismeran autogene, the personalized mRNA cancer therapy Moderna is developing with Merck, are scheduled to be presented at the European Society for Medical Oncology meeting on Oct. 24 at 22:30 Beijing time, followed by an investor event at 01:00 on Oct. 25. The companies had said on Aug. 19 that the therapy in combination with Keytruda met the primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. TradingBeats data also showed a whale address beginning with 0x4e23 holding a roughly $4.518 million 10x isolated short in MRNA on Hyperliquid, with an estimated liquidation price of $248.37.

1180
Moderna jumps 11% in two sessions as whale short nears liquidation before cancer data release
Moderna
Oct 9, 2026

Moderna joins the Nasdaq-100 as leveraged on-chain traders target higher MRNA prices

Moderna is set to enter the Nasdaq-100 before the U.S. market opens on Oct. 9 Beijing time, replacing Warner Bros. Discovery in an index change that was announced on Oct. 1. From the Oct. 1 U.S. close before the announcement to the latest close on Oct. 8, MRNA rose from $188.94 to $197, a gain of about 4.27%. The company, known for developing vaccines and therapeutics based on mRNA technology, has research programs spanning infectious diseases, cancer and rare diseases. Beyond its vaccine business, Moderna and Merck reported positive Phase 3 results in August for a personalized mRNA cancer therapy. The trial met its primary endpoint of recurrence-free survival in adjuvant melanoma treatment, which the source described as a key catalyst for the stock. TradingBeats data showed MRNA on-chain contracts at $196.45, up about 0.56% over 24 hours, with open interest of roughly 15,600 contracts and notional value of about $3.059 million. The second-largest long holder, using 10x leverage, placed a market take-profit trigger at $350 for the full position, around 77.9% above the current price.

1050
Moderna joins the Nasdaq-100 as leveraged on-chain traders target higher MRNA prices
cancer vaccine
Sep 8, 2026

Tempus AI Could See Over $600M in Annual Revenue from Cancer Vaccine Sequencing, Analysts Say

Moderna and Merck's personalized cancer vaccines have added over $50 billion in market value to the two drugmakers. The diagnostic sequencing process behind these vaccines is emerging as a new investment opportunity. Tempus AI, as a sequencing partner for the Moderna-Merck vaccine, could benefit if the vaccine is approved. Piper Sandler estimates the melanoma vaccine alone could generate at least $50 million in annual sequencing revenue, while BTIG analyst Mark Massaro projects the figure could exceed $600 million. The post-treatment cancer recurrence monitoring market via blood tests is seen as a multi-billion-dollar opportunity, but Natera currently dominates. However, uncertainties remain in the mRNA cancer vaccine field, and pharma companies may internalize some sequencing work in the future.

1970
Tempus AI Could See Over $600M in Annual Revenue from Cancer Vaccine Sequencing, Analysts Say
Biotech
Aug 26, 2026

Biotech shares rally across U.S. and Hong Kong as Moderna jumps 14% and CanSino rises more than 17%

Biotech stocks posted sharp gains across U.S. and Hong Kong markets on Aug. 26, according to market data cited by BlockBeats. Moderna (MRNA) closed up 14.36% in U.S. trading with turnover reaching $7.636 billion, while Merck (MRK) gained 3.84%. The move followed a recent joint announcement from Moderna and Merck that their first personalized mRNA cancer therapy, intismeran autogene, succeeded in a global Phase III clinical trial for high-risk melanoma. After that update, several major banks raised their price targets on Moderna, including Bank of America, Piper Sandler, Goldman Sachs, JPMorgan, and Barclays. In Hong Kong trading, CanSino Biologics rose 17% after the open, while Innovent Biologics gained more than 10%, Everest Medicines rose more than 7%, Akeso climbed more than 6%, and RemeGen advanced more than 4%. CanSino also said its subsidiary CanSino Shanghai had formally signed a strategic framework agreement with DeepVessel Biopharma to jointly develop and commercialize personalized therapeutic mRNA tumor vaccines.

2100
Biotech shares rally across U.S. and Hong Kong as Moderna jumps 14% and CanSino rises more than 17%
Binance
Aug 25, 2026

Binance to list five USDT-margined TradFi perpetual contracts with up to 20x leverage

Binance said it will roll out five USDT-margined perpetual contracts on August 25 between 17:00 and 17:20 UTC+8, adding SKUUUSDT, SKDDUSDT, RAMUSDT, DJTUSDT, and MRNAUSDT in phases. According to the official announcement, the underlying exposure for these products includes traditional financial assets such as a Hynix leveraged ETF, a DRAM-themed ETF, Trump Media & Technology (DJT), and Moderna (MRNA). All five contracts will be settled in USDT and will support round-the-clock trading as well as Multi-Assets Mode. Binance also said the maximum leverage available on these contracts will be 20x. Funding fees will be settled once every eight hours, with the upper and lower caps set at +2% and -2%, respectively. The listing adds another batch of TradFi-linked derivatives to Binance’s futures lineup.

1620
Binance to list five USDT-margined TradFi perpetual contracts with up to 20x leverage
Moderna
Aug 20, 2026

Moderna shares jump 176.97% after melanoma vaccine trial success with Merck

Moderna and Merck said their jointly developed mRNA melanoma vaccine trial met its goal, setting off a sharp rally in biopharma stocks. Moderna shares surged as much as 176.97% on Wednesday and closed at $174, marking the company’s biggest single-day gain on record, according to ABMedia. Merck also rose more than 12.60% to $152.20. The report said the vaccine candidate, Intismeran Autogene, used in combination with Merck’s Keytruda, reduced the risk of recurrence for some melanoma patients. Leerink Partners analyst Daina Graybosch called the Phase 3 trial result “historic.” ABMedia also said the move lifted shares of BioNTech, AbbVie, Amgen, Eli Lilly and Johnson & Johnson. The outlet added that Moderna’s latest progress came after weaker COVID-19 vaccine demand had left investors watching its transition strategy closely, while recent sector rotation had started bringing capital back into healthcare and biotech stocks.

2310
Moderna shares jump 176.97% after melanoma vaccine trial success with Merck